Analyst Price Target is $12.00
▲ +391.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Alpha Tau Medical in the last 3 months. The average price target is $12.00, with a high forecast of $23.00 and a low forecast of $8.00. The average price target represents a 391.80% upside from the last price of $2.44.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Alpha Tau Medical. This Buy consensus rating has held steady for over two years.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Read More